论文部分内容阅读
应用国产ELISA试剂盒对157例肝癌、肝硬化病人血清中抗-HCV及HBV-M进行检测，101例肝癌10例抗-HCV阳性，阳性率为9．9％；56例肝硬化6例抗-HCV阳性，阳性率为10．7％；肝癌组抗HCV与HBsAg双阳性率79％（8／101），HBsAg阳性率为723％（73／101），明显高于HCV感染率，说明HBV仍是乙肝流行地区的主要相关因素。14例抗-HCV阳性（包括可疑阳性），肝癌外周血中8例（57．1％）HBsAg阳性，推测HCV可单独作用但更常与HBV形成混合感染参与慢性肝病的癌变过程。
Anti-HCV and HBV-M were detected in serum of 157 patients with hepatocellular carcinoma and cirrhosis by domestic ELISA kit. 10 cases of 101 cases of hepatocellular carcinoma were positive for anti-HCV, the positive rate was 9.9%; 56 cases of liver cirrhosis were resistant to 6 cases. - positive for HCV, positive rate was 10.7%; anti-HCV and HBsAg double positive rate in liver cancer group was 79% (8/101), and HBsAg positive rate was 7223% (73/101), significantly higher than HCV infection rate, indicating HBV It is still a major factor in the prevalence of hepatitis B. In 14 cases of anti-HCV positive (including suspicious positive), 8 cases (57.1%) of peripheral blood of hepatocellular carcinoma were positive for HBsAg. It is speculated that HCV can act alone but more often form mixed infection with HBV to participate in the carcinogenesis of chronic liver disease.